FDA weighs noninvasive biopsy alternative in MASH clinical trials
The U.S. Food and Drug Administration (FDA) will evaluate the use of Fibroscan, a noninvasive test, to replace liver biopsies in clinical trials for metabolic…
Lindsey Shapiro, PhD, Science Writer—
Articles by Lindsey Shapiro
Virtual 5K expands annual run into national biliary atresia fundraiser
An annual fundraising run in the Washington area becomes a monthlong, virtual event this year to raise funds and awareness for the rare pediatric liver…
Phase 3 Trial of brelovitug for hepatitis D enrolls 1st patient
The first participant has been enrolled in a Phase 3 clinical trial testing Bluejay Therapeutics’ investigational therapy brelovitug against bulevirtide in adults with chronic…
Treatment of hepatitis B needs global overhaul, per WHO study
Current approaches to hepatitis B care across the globe are failing to adequately connect patients with treatment, and also to retain them for long-term…
Dosing begins in Phase 2 trial of ALG-000184 for hepatitis B
The first participant has been dosed in a Phase 2 clinical trial testing Aligos Therapeutics’ oral treatment candidate ALG-000184 in people chronically infected with…
Study reveals disease mechanisms that may drive biliary atresia
A new preclinical study has found that a combination of viral and bacterial insults may be a key disease mechanism underlying biliary atresia. Specifically,…
Hepatitis C treatment rates low among some at-risk US populations
Access to hepatitis C treatment and care remains low among children and recently pregnant women in the U.S., according to data from two recently…
Umecrine raises $2.5M to advance trial testing golexanolone for PBC
Umecrine Cognition has raised around $2.5 million to support an ongoing Phase 1b/2a clinical trial testing its investigational therapy golexanolone for cognitive problems and…
Pemvidutide shows benefit for MASH in Phase 2b clinical trial
Pemvidutide resolved metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver disease, without worsening liver scarring (fibrosis) for more than half of people…
Diabetes drug dapagliflozin shows benefits for MASH in Phase 3 trial
Daily treatment with the diabetes medication dapagliflozin eased disease severity for people with metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver disease,…